ArticleAmerican journal of respiratory and critical care medicine2016
A Novel CD4
Article in American journal of respiratory and critical care medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 38 citations in OpenAlex.
- Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2017Trial
- Modulation of host lung immunity in Pneumocystis pneumonia: a review of current concepts and future prospects for novel adjunctive immune-based therapies.Journal of immunology (Baltimore, Md. : 1950) · 2026Review
- Immune Responses toJournal of inflammation research · 2026Review
- Immune responses of different hosts toEuropean respiratory review : an official journal of the European Respiratory Society · 2025Review
- T-cell subsets inClinical & translational immunology · 2025Review
- Role of the FungusInternational journal of molecular sciences · 2024Article
- Gut Mycobiome and Asthma.Journal of fungi (Basel, Switzerland) · 2024Review
- Article
- Integrated multi-omics analyses reveal the altered transcriptomic characteristics of pulmonary macrophages in immunocompromised hosts withFrontiers in immunology · 2023Article
- The first detection of Pneumocystis jirovecii in asthmatic patients post-COVID-19 in Jordan.Bosnian journal of basic medical sciences · 2022Article
- Concurrent Infection with SARS-CoV-2 andJournal of fungi (Basel, Switzerland) · 2022Review
- Refractory flare-up of severe bronchial asthma controlled with mepolizumab due to Pneumocystis pneumonia: a case report.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2022Article
- The association of trimethoprim-sulfamethoxazole with improved lung function in pediatric asthma.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2021Article
- Relationship ofBMJ open respiratory research · 2021Article
- How can we minimise the use of regular oral corticosteroids in asthma?European respiratory review : an official journal of the European Respiratory Society · 2020Review
- Bronchoscopy in severe childhood asthma: Irresponsible or irreplaceable?Pediatric pulmonology · 2020Review
- Review
- Interactions of Bacteriophages and Bacteria at the Airway Mucosa: New Insights Into the Pathophysiology of Asthma.Frontiers in allergy · 2020Review
- Transcriptomic and Proteomic Approaches to Finding Novel Diagnostic and Immunogenic Candidates inmSphere · 2019Article
- The Contribution of Host Cells toPathogens (Basel, Switzerland) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
Abstract
rationaleInfection with Pneumocystis, an opportunistic fungal pathogen, can result in fulminant pneumonia in the clinical setting of patients with immunosuppression. In murine models, Pneumocystis has previously been shown to induce a CD4
objectivesWe sought to explore the role of Pneumocystis in generating asthma-like lung pathology, given the natural eosinophilic response to infection.
methodsPneumocystis infection or antigen treatment was used to induce asthma-like pathology in wild-type mice. The roles of CD4 MEASUREMENTS AND MAIN
resultsPneumocystis infection generates a strong type II response in the lung that requires CD4
conclusionsThe present study demonstrates for the first time, to our knowledge, that Pneumocystis is an airway allergen capable of inducing asthma-like lung pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.